Is Overall Sentiment on Natera Bearish?

By Scott Lee • Thursday, June 15 12:07 • Permanent Link

Natera stock is trading -32.92% below its average target price of $73.79 after dropping -1.9% during today's afternoon session. Analysts are giving the mid-cap Medical Specialities company an average rating of buy and target prices ranging from $29.0 to $117.0 per share.

Natera has an average level of shares sold short, at 6.3% of its total share float. The stock's short ratio (also called days to cover) is 6.31. Since 3.73% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 96.5% of Natera's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Natera

Date Reported	Holder	Percentage	Shares	Value
2023-03-31	Vanguard Group, Inc. (The)	9%	10,161,365	$502,936,749
2023-03-31	Fred Alger Management, LLC	7%	7,818,925	$386,997,684
2023-03-31	JP Morgan Chase & Company	6%	6,645,333	$328,910,749
2023-03-31	Blackrock Inc.	5%	5,509,384	$272,686,955
2023-03-31	Sofinnova Investments, Inc.	3%	3,100,560	$153,462,213
2023-03-31	Kynam Capital Management, LP	3%	2,918,237	$144,438,137
2023-03-31	Citadel Advisors Llc	2%	2,827,676	$139,955,820
2023-03-31	Eversept Partners, LP	2%	2,819,770	$139,564,513
2022-12-31	Norges Bank Investment Management	2%	2,780,428	$137,617,280
2023-03-31	State Street Corporation	2%	2,747,338	$135,979,491

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.